WuXi Biologics Receives IMAPAC Bioprocessing Excellence Award
SINGAPORE, April 14, 2022 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a global contract research, development and manufacturing organization (CRDMO) services company, today announced that the company has received the Bioprocessing Excellence Award for Viral Clearance and Safety at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event. This is the second year in a row that WuXi Bio has received this award from IMAPAC, a leading consulting firm in the biopharmaceutical industry.
Since 2015, WuXi Biologics has been providing viral clearance biosafety testing services for a variety of biotherapeutic product types, including monoclonal and bispecific antibodies, fusion proteins, peptides, and other recombinant proteins. Data from these viral clearance studies successfully support WuXi Biologic’s customers in their Investigational New Drug (IND) or Biologics License Application (BLA) submissions. To date, more than 500 viral clearance studies submitted with its customers’ IND and BLA filings have been approved by global regulatory agencies (eg, US FDA, EMA, NMPA, PMDA, TGA). This achievement further demonstrates the company’s excellent track record in project execution and compliance.
dr. Chris ChenCEO of WuXi Biologics, commented“To be recognized for two consecutive years by IMAPAC with the Bioprocessing Excellence in Viral Clearance and Safety award is a great honor for our company and our employees. The award reflects our commitment to providing high quality biosafety testing services to our partners as a global R&DMC service provider. This achievement will further inspire us to enhance our capacity and capabilities to enable global partners and benefit patients worldwide.”
The Asia-Pacific Bioprocessing Excellence Awards aim to recognize outstanding bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at increased speed, reduced cost and higher quality.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a global contract research, development and manufacturing organization (CRDMO) providing end-to-end solutions that enable partners to discover, develop and manufacture biologics , from concept to market, benefiting patients around the world. .
With over 10,000 skilled employees in China, United States, Germany, Ireland and Singapore, WuXi Biologics leverages its technologies and expertise to provide its customers with efficient and cost-effective solutions for the discovery, development and manufacturing of biologics. As of the end of 2021, WuXi Biologics is supporting more than 480 integrated customer projects, including nine in commercial manufacturing.
WuXi Biologics views environmental, social and governance (ESG) responsibilities as an integral part of our business philosophy and strategy, and we aim to become an ESG leader in the CRDMO biologics industry. Our facilities use next-generation biomanufacturing technologies and clean energy sources. We have also set up an ESG committee led by our CEO to drive the overall ESG strategy and its implementation, reinforcing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
SOURCE 药明生物 (WuXi Biologics)